

²Department of Laboratory Medicine, Nanjing Red Cross Blood Center, Nanjing, Jiangsu 210003, China

³Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, Hubei 430100, China

⁴Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, Hubei 430100, China

Correspondence to Professor Xinyi Xia, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, China; xiaynju@163.com

Correction notice This article has been corrected since it published Online First. The title has been corrected.

Contributors JZ and RP conducted data analysis and wrote the manuscript. LZ contributed with comments during the writing. JW, YG and YY conducted data analysis. XX and LZ conceived the study.

Funding Key Foundation of Wuhan Huoshenshan Hospital (2020[18]), Key Research & Development Program of Jiangsu Province (BE2018713), Medical Innovation Project of Logistics Service (18JS005).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

JZ, RP and JW contributed equally.



To cite Zhao J, Pang R, Wu J, *et al.* *Ann Rheum Dis* 2021;**80**:e63.

Received 1 June 2020

Accepted 2 June 2020

Published Online First 16 June 2020



► <https://doi.org/10.1136/annrheumdis-2020-218196>

Ann Rheum Dis 2021;**80**:e63. doi:10.1136/annrheumdis-2020-218183

ORCID iD

Xinyi Xia <http://orcid.org/0000-0002-7178-0505>

REFERENCES

- 1 D'Silva KM, Serling-Boyd N, Wallwork R, *et al.* Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. *Ann Rheum Dis* 2020;79:1156–62.
- 2 Mathian A, Amoura Z. Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine' by Nikipour *et al.* *Ann Rheum Dis* 2021;80:e34.
- 3 Mathian A, Mahevas M, Rohmer J, *et al.* Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. *Ann Rheum Dis* 2020;79:837–9.
- 4 Nikipour M, Teh B, Wicks IP, *et al.* Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'. *Ann Rheum Dis* 2021;80:e33.
- 5 Hu K, Guan W-J, Bi Y, *et al.* Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. *Phytomedicine* 2020:153242.